C12N 2320/00
Applications
Official title: Applications; Uses
C12N2320/00 (Applications) appears on 5,709 US grants and 11,783 published applications in this corpus.
Search patents in C12N- Granted patents
- 5,709
- Published applications
- 11,783
- Assignees
- 2,724
- Inventors
- 15,268
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 2 | 0 |
| 1998 | 5 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 6 |
| 2003 | 2 | 41 |
| 2004 | 3 | 77 |
| 2005 | 2 | 165 |
| 2006 | 9 | 151 |
| 2007 | 9 | 208 |
| 2008 | 13 | 202 |
| 2009 | 70 | 298 |
| 2010 | 116 | 332 |
| 2011 | 135 | 338 |
| 2012 | 188 | 407 |
| 2013 | 205 | 385 |
| 2014 | 274 | 501 |
| 2015 | 324 | 658 |
| 2016 | 410 | 829 |
| 2017 | 463 | 688 |
| 2018 | 476 | 658 |
| 2019 | 475 | 696 |
| 2020 | 402 | 680 |
| 2021 | 403 | 808 |
| 2022 | 409 | 882 |
| 2023 | 353 | 786 |
| 2024 | 350 | 813 |
| 2025 | 350 | 712 |
| 2026 | 250 | 461 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Compositions and methods for reprogramming age-restricted non-neuronal cells29 Sep 2026US 12,747,438 B2The Regents of the University of California
- Nutritional composition comprising miR-312629 Sep 2026US 12,747,439 B2Societe des Produits Nestle S. A.
- Antisense oligonucleotides for the treatment of stargardt disease29 Sep 2026US 12,747,440 B2ProQR Therapeutics II B.V.
- Riboswitch modulated gene therapy for retinal diseases29 Sep 2026US 12,747,441 B2The Medical College of Wisconsin, Inc.
- Adenine base editors with reduced off-target effects8 Oct 2026US 2026/0308561 A1President and Fellows of Harvard College
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for regulating expression of atxn28 Oct 2026US 2026/0308591 A1Riboway Therapeutics, Inc.
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
Most cited
By later US patents
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Engineering of systems, methods and optimized guide compositions for sequence manipulation480US 8,906,616 B2Massachusetts Institute of Technology · 2014